Literature DB >> 11916316

Impact of new mutations in the methylenetetrahydrofolate reductase gene assessed on biochemical phenotypes: a familial study.

C Tonetti1, J Amiel, A Munnich, J Zittoun.   

Abstract

Methylenetetrahydrofolate reductase (MTHFR) deficiency was identified in two out of four children born from nonconsanguineous parents. One of the affected children exhibited some clinical findings suggesting cystathionine beta-synthase deficiency; MTHFR activity was extremely reduced. In addition, hyperhomocysteinaemia, hypomethioninaemia, low total folate, especially methylfolate in red blood cells, and a reduced methylfolate/total folate ratio were found. Two mutations not yet reported, one on exon 1 of the gene changing an arginine to stop codon and one other on exon 9 changing an arginine to tryptophan were identified in both children in the compound heterozygous state associated with a common polymorphism, 1298A>C, also in the heterozygous state. The mother, homozygous for the mutation on exon 9 and for the polymorphism 1298A>C on exon 7, was clinically and biochemically normal, with normal folate status, mainly methylfolate levels in red blood cells, although MTHFR activity was moderately decreased. The father, heterozygous for the transition arginine to stop codon and for the common polymorphism 677C>T on exon 4, exhibited major biochemical abnormalities, hyperhomocysteinaemia and low methylfolate levels in red blood cells, but was clinically normal. The unaffected children had a biochemical pattern close to that of their mother and were heterozygous for the mutation on exon 9 and also for the two common polymorphisms, 677C>T and 1298A>C. In the affected children, some biochemical abnormalities, including folate status, especially methylfolate levels, were improved with treatment combining methyltetrahydrofolic acid, hydroxocobalamin, pyridoxine and betaine; however, homocysteine concentrations remained high and methionine concentrations were lowered. The father was treated with folic acid, which partially improved biochemical abnormalities. The impact of these mutations is discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11916316     DOI: 10.1023/a:1013988123902

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  17 in total

Review 1.  Remethylation defects: guidelines for clinical diagnosis and treatment.

Authors:  H Ogier de Baulny; M Gérard; J M Saudubray; J Zittoun
Journal:  Eur J Pediatr       Date:  1998-04       Impact factor: 3.183

2.  Methylenetetrahydrofolate reductase thermolabile variant and human longevity.

Authors:  L Faure-Delanef; I Quéré; J F Chassé; O Guerassimenko; M Lesaulnier; H Bellet; J Zittoun; P Kamoun; D Cohen
Journal:  Am J Hum Genet       Date:  1997-04       Impact factor: 11.025

3.  Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study.

Authors:  Isabelle Quéré; Thomas V Perneger; Jacqueline Zittoun; Hélène Bellet; Jean-Christophe Gris; Jean-Pierre Daurès; Jean-François Schved; Eric Mercier; Jean-Pierre Laroche; Michel Dauzat; Henri Bounameaux; Charles Janbon; Philippe de Moerloose
Journal:  Lancet       Date:  2002-03-02       Impact factor: 79.321

4.  Methylenetetrahydrofolate reductase deficiency revealed by a neuropathy in a psychotic adult.

Authors:  F Pasquier; F Lebert; H Petit; J Zittoun; J Marquet
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-06       Impact factor: 10.154

5.  Characterization of six novel mutations in the methylenetetrahydrofolate reductase (MTHFR) gene in patients with homocystinuria.

Authors:  S Sibani; B Christensen; E O'Ferrall; I Saadi; F Hiou-Tim; D S Rosenblatt; R Rozen
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

6.  Severe and mild mutations in cis for the methylenetetrahydrofolate reductase (MTHFR) gene, and description of five novel mutations in MTHFR.

Authors:  P Goyette; B Christensen; D S Rosenblatt; R Rozen
Journal:  Am J Hum Genet       Date:  1996-12       Impact factor: 11.025

7.  A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity.

Authors:  I Weisberg; P Tran; B Christensen; S Sibani; R Rozen
Journal:  Mol Genet Metab       Date:  1998-07       Impact factor: 4.797

8.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase.

Authors:  P Frosst; H J Blom; R Milos; P Goyette; C A Sheppard; R G Matthews; G J Boers; M den Heijer; L A Kluijtmans; L P van den Heuvel
Journal:  Nat Genet       Date:  1995-05       Impact factor: 38.330

9.  Gene structure of human and mouse methylenetetrahydrofolate reductase (MTHFR)

Authors:  P Goyette; A Pai; R Milos; P Frosst; P Tran; Z Chen; M Chan; R Rozen
Journal:  Mamm Genome       Date:  1998-08       Impact factor: 2.957

10.  Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency.

Authors:  P Goyette; P Frosst; D S Rosenblatt; R Rozen
Journal:  Am J Hum Genet       Date:  1995-05       Impact factor: 11.025

View more
  3 in total

1.  Methylenetetrahydrofolate reductase deficiency (homocystinuria type II) as a rare cause of rapidly progressive tetraspasticity and psychosis in a previously healthy adult.

Authors:  T Birnbaum; H J Blom; H Prokisch; M Hartig; T Klopstock
Journal:  J Neurol       Date:  2008-10-07       Impact factor: 4.849

2.  Haplotype analysis of the folate-related genes MTHFR, MTRR, and MTR and migraine with aura.

Authors:  Kathryn A Roecklein; Ann I Scher; Albert Smith; Tamara Harris; Gudny Eiriksdottir; Melissa Garcia; Villi Gudnason; Lenore J Launer
Journal:  Cephalalgia       Date:  2013-02-19       Impact factor: 6.292

3.  Relations between molecular and biological abnormalities in 11 families from siblings affected with methylenetetrahydrofolate reductase deficiency.

Authors:  Carole Tonetti; Jean-Marie Saudubray; Bernard Echenne; Pierre Landrieu; Stéphane Giraudier; Jacqueline Zittoun
Journal:  Eur J Pediatr       Date:  2003-05-06       Impact factor: 3.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.